Join the club for FREE to access the whole archive and other member benefits.

Is This the Anti-Aging Pill We’ve All Been Waiting For?


Key points from article :

Novartis sought to see whether giving low doses of everolimus to people over 65 increased their response to flu vaccines.

Called the “first human aging trial” as it looked at whether the immune system of elderly people could be made to act younger.

Startup resTORbio is licensing two drug molecules for aging-related disease.

Will further test whether such drugs can rejuvenate aged immune cells.

Everolimus is a derivative of rapamycin – which makes mice live 25% longer.

Mentioned in this article:

Click on resource name for more details.

Brian Kennedy

Prof of Biochemistry and Physiology at NUS, CSO Ponce De Leon Health

Chen Schor

Founder, President, CEO, Secretary & Director, resTORbio, Inc.

David Harrison

Professor and Senior Staff Scientist at The Jackson Laboratory.

Joseph Bolen

Chief Scientific Officer at PureTech Health.


Global medicines company for developing and producing drugs.

PureTech Health

Biotherapeutics co developing new medicines for devastating diseases.


Biopharmaceutical company developing therapeutics for aging-related diseases.

Topics mentioned on this page: